Wikisage, the free encyclopedia of the second generation, is digital heritage
Aspirin: Difference between revisions
Jump to navigation
Jump to search
m (hide) |
m (→Links) |
||
| (7 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
<ref>[https://www.mdpi.com/2077-0383/8/1/104/htm Clopidogrel versus Ticagrelor for Secondary Prevention after Coronary Artery Bypass Grafting]</ref> | <ref>[https://www.mdpi.com/2077-0383/8/1/104/htm Clopidogrel versus Ticagrelor for Secondary Prevention after Coronary Artery Bypass Grafting]</ref> | ||
[[File:Kawasaki_tongue_1.jpg|thumb]] | [[File:Kawasaki_tongue_1.jpg|thumb]] | ||
==Kawasaki== | ==[[Kawasaki disease|Kawasaki]]== | ||
Protocols recommend AAs and intravenous immunoglubin; however many cases have be shown to be refractory to this treatment | Protocols recommend AAs and intravenous immunoglubin; however many cases have be shown to be refractory to this treatment | ||
<ref>[http://www.e-mjm.org/2018/v73n6/refractory-kawasaki-disease.pdf A case report of refractory kawasaki disease]</ref> | <ref>[http://www.e-mjm.org/2018/v73n6/refractory-kawasaki-disease.pdf A case report of refractory kawasaki disease]</ref> | ||
==Hutchinson | ==[[Hutchinson-Gilford Progeria]]== | ||
[[File:Progeri n1.jpg|thumb]] | |||
Low dosis Aspirin 2-3 mg/Kg body weight is recommended for prevention of cardiovascular and stroke complications | Low dosis Aspirin 2-3 mg/Kg body weight is recommended for prevention of cardiovascular and stroke complications | ||
<ref>[https://www.ncbi.nlm.nih.gov/pubmed/20301300 Hutchinson-Gilford Progeria Syndrome]</ref> | <ref>[https://www.ncbi.nlm.nih.gov/pubmed/20301300 Hutchinson-Gilford Progeria Syndrome]</ref> | ||
==[[ATC]]== | ==[[ATC]]== | ||
[[File:Under construction icon.png|thumb|left]] | |||
[[File:Aspirin-B-3D-balls.png|thumb]] | |||
Salicylic acid and derivates | Salicylic acid and derivates | ||
*Acetylsalicylic acid (INN) | *Acetylsalicylic acid (INN) | ||
| Line 23: | Line 27: | ||
<references/> | <references/> | ||
[[nl:aspirine]] | |||
{{Wikidata|Q18216}} | {{Wikidata|Q18216}} | ||
[[Category:World Health Organization essential medicines]] | |||
Latest revision as of 01:36, 26 January 2019
Aspirin is an NSAID [1] A recommendation of AAs-clopidogrel to maintain the patency of the stent following coronary intervention. Clopidogrel is a P2Y12 inhibiting platelet agent; the combination AAs Ticagrelor wasn´t better than clopidogrel+aspirin [2]
Kawasaki
Protocols recommend AAs and intravenous immunoglubin; however many cases have be shown to be refractory to this treatment [3]
Hutchinson-Gilford Progeria
Low dosis Aspirin 2-3 mg/Kg body weight is recommended for prevention of cardiovascular and stroke complications [4]
ATC
Salicylic acid and derivates
- Acetylsalicylic acid (INN)
